- Home
- PMM vs HRTX Comparison
PMM vs HRTX Comparison
Compare PMM & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | HRTX |
|---|---|---|
| Founded | 1989 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.4M | 203.5M |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | PMM | HRTX |
|---|---|---|
| Price | $6.17 | $1.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 118.3K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $155,097,000.00 |
| Revenue This Year | N/A | $8.98 |
| Revenue Next Year | N/A | $11.57 |
| P/E Ratio | $26.52 | ★ N/A |
| Revenue Growth | N/A | ★ 12.60 |
| 52 Week Low | $5.00 | $1.00 |
| 52 Week High | $6.42 | $2.68 |
Technical Indicators
Market Signals| Indicator | PMM | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.97 | 54.20 |
| Support Level | $6.10 | $1.26 |
| Resistance Level | $6.21 | $1.40 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 100.00 | 56.01 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.